JP2005523718A5 - - Google Patents

Download PDF

Info

Publication number
JP2005523718A5
JP2005523718A5 JP2004501545A JP2004501545A JP2005523718A5 JP 2005523718 A5 JP2005523718 A5 JP 2005523718A5 JP 2004501545 A JP2004501545 A JP 2004501545A JP 2004501545 A JP2004501545 A JP 2004501545A JP 2005523718 A5 JP2005523718 A5 JP 2005523718A5
Authority
JP
Japan
Prior art keywords
seq
nucleic acid
copy
isolated polynucleotide
factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004501545A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005523718A (ja
Filing date
Publication date
Priority claimed from US10/135,447 external-priority patent/US7067649B2/en
Application filed filed Critical
Publication of JP2005523718A publication Critical patent/JP2005523718A/ja
Publication of JP2005523718A5 publication Critical patent/JP2005523718A5/ja
Pending legal-status Critical Current

Links

JP2004501545A 2002-05-01 2003-04-30 内皮細胞特異性を示すプロモーター及びその使用法 Pending JP2005523718A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/135,447 US7067649B2 (en) 2000-11-17 2002-05-01 Promoters exhibiting endothelial cell specificity and methods of using same
PCT/IL2003/000347 WO2003093409A2 (en) 2002-05-01 2003-04-30 Promoters exhibiting endothelial cell specificity and methods of using same

Publications (2)

Publication Number Publication Date
JP2005523718A JP2005523718A (ja) 2005-08-11
JP2005523718A5 true JP2005523718A5 (cg-RX-API-DMAC7.html) 2006-05-25

Family

ID=29399218

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004501545A Pending JP2005523718A (ja) 2002-05-01 2003-04-30 内皮細胞特異性を示すプロモーター及びその使用法

Country Status (9)

Country Link
US (1) US7067649B2 (cg-RX-API-DMAC7.html)
EP (1) EP1527084A4 (cg-RX-API-DMAC7.html)
JP (1) JP2005523718A (cg-RX-API-DMAC7.html)
KR (1) KR20040104685A (cg-RX-API-DMAC7.html)
CN (1) CN1703420A (cg-RX-API-DMAC7.html)
CA (1) CA2483996A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA04010711A (cg-RX-API-DMAC7.html)
WO (1) WO2003093409A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200408989B (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003222427B8 (en) 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US8039261B2 (en) * 2000-11-17 2011-10-18 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US20100282634A1 (en) * 2000-11-17 2010-11-11 Dror Harats Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis
US20070286845A1 (en) * 2000-11-17 2007-12-13 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US8071740B2 (en) * 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US6838452B2 (en) * 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
EP1436313B1 (en) * 2001-10-19 2010-09-22 Vascular Biogenics Ltd. Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
AU2011205076B2 (en) * 2004-11-14 2012-03-15 Vascular Biogenics Ltd. Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis
US20060148695A1 (en) * 2005-01-03 2006-07-06 National Cheng Kung University Novel angiogenic composition and use thereof
US20070161031A1 (en) * 2005-12-16 2007-07-12 The Board Of Trustees Of The Leland Stanford Junior University Functional arrays for high throughput characterization of gene expression regulatory elements
WO2008015675A2 (en) 2006-07-31 2008-02-07 Vascular Biogenics Ltd. Polypeptides and polynucleotides encoding same and use thereof in the treatment of medical conditions associated with ischemia
EP2135080A4 (en) * 2007-03-08 2010-12-01 Switchgear Genomics FUNCTIONAL NETWORKS FOR THE CHARACTERIZATION OF TREATMENT OF REGULATORY ELEMENTS IN NON-TRANSLATED REGIONS OF GENES
US20090136465A1 (en) 2007-09-28 2009-05-28 Intrexon Corporation Therapeutic Gene-Switch Constructs and Bioreactors for the Expression of Biotherapeutic Molecules, and Uses Thereof
US8815779B2 (en) 2009-09-16 2014-08-26 SwitchGear Genomics, Inc. Transcription biomarkers of biological responses and methods
MX342641B (es) 2010-01-05 2016-10-07 Vascular Biogenics Ltd Metodos para uso de un agente adenoviral anti-angiogenico especifico.
MX338931B (es) 2010-01-05 2016-05-06 Vascular Biogenics Ltd Composiciones y metodo para tratar gliobastoma (gbm).
KR101989171B1 (ko) 2012-10-17 2019-06-14 바스큘라 바이오제닉스 리미티드 아데노바이러스를 사용하는 치료 방법
EP2951306A4 (en) 2013-01-30 2016-07-27 Univ Nebraska COMPOSITIONS AND METHOD FOR TREATING COMPLICATIONS RELATED TO DIABETES
US9682154B2 (en) 2013-02-04 2017-06-20 Vascular Biogenics Ltd. Methods of inducing responsiveness to anti-angiogenic agent
WO2021095809A1 (ja) * 2019-11-15 2021-05-20 国立大学法人大阪大学 心不全に応答するエンハンサーポリヌクレオチド、及び前記エンハンサーポリヌクレオチドを含む発現ベクター

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747340A (en) * 1994-06-03 1998-05-05 Syntex (U.S.A.) Inc. Targeted gene expression using preproendothelin-1 promoters
AU5318299A (en) * 1998-07-27 2000-02-21 Valentis, Inc. Anti-angiogenesis plasmids and delivery systems, and methods of making and using the same
ES2338529T3 (es) * 2000-11-17 2010-05-10 Vascular Biogenics Ltd. Prometores que exiben especificidad por celulas endoteliales y metodos para su utilizacion.

Similar Documents

Publication Publication Date Title
US6573092B1 (en) Method of preparing a eukaryotic viral vector
Li et al. Synthetic muscle promoters: activities exceeding naturally occurring regulatory sequences
JP2022166077A5 (cg-RX-API-DMAC7.html)
Szybalski et al. Transcriptional units and their controls in Escherichia coli phage λ: operons and scriptons
JP2010525805A5 (cg-RX-API-DMAC7.html)
Hentsch et al. The weak, fine-tuned binding of ubiquitous transcription factors to the II-2 enhancer contributes to its T cell-restricted activity
JP2006115849A5 (cg-RX-API-DMAC7.html)
JP2003528604A5 (cg-RX-API-DMAC7.html)
Jacobs et al. Prospects of viral vector-mediated delivery of sequences encoding anti-HBV designer endonucleases
Mellado et al. High level synthesis in Escherichh coli of the Bacillus subtilis phage ø29 proteins p3 and p4 under the control of phage lambda P L promoter
JP2007522797A5 (cg-RX-API-DMAC7.html)
CN108840947A (zh) 牛白蛋白-干扰素α-白介素2融合蛋白、制备方法及其编码基因、一种牛长效干扰素
Nunokawa et al. Expression of human inducible nitric oxide synthase is regulated by both promoter and 3′-regions
Morino et al. Construction of a runaway vector and its use for a high-level expression of a cloned human superoxide dismutase gene
WO2025087435A1 (zh) 一种来源于asmt基因的启动子元件及其应用
JP4402457B2 (ja) アデノウイルスe2後期プロモーターの制御のための、インビトロにおけるyb−1の使用、及び、腫瘍の治療を目的とする医薬の製造のための当該使用を活用した核酸構築物の使用
JP2009507474A5 (cg-RX-API-DMAC7.html)
CN104513830B (zh) 一种适用于氧化葡萄糖酸杆菌的基因表达载体及其应用
US7368553B2 (en) Alternatively spliced nucleic acid molecules
McKay et al. An enzyme-linked immunosorbent assay for the detection of agents which interfere with the DNA binding activities of transcription factors—exemplified by NF-IL6
CN107253996A (zh) 羊白蛋白‑干扰素τ‑白介素2融合蛋白、制备方法及其编码基因、一种羊长效干扰素
CN107353348A (zh) 一种重组羊长效干扰素τ及制备此长效干扰素的融合蛋白及其制备方法
JP2005531302A5 (cg-RX-API-DMAC7.html)
Takimoto et al. Gene regulation by the 5′-untranslated region of the platelet-derived growth factor A-chain
CN116710554B (zh) 基因工程改造获得的分泌能力和凝血活性增强的人类八因子